Christina Gamba-Vitalo, PhD
Head of in vivo Pharmacology and Toxicology

Christina Gamba-Vitalo received her MS and PhD in Experimental Hematology at New York University, followed by postdoctoral research positions at Yale University School of Medicine. Christina's first industrial position was at Proctor & Gamble. She then moved to EG&G Mason Labs/Genzyme Transgenics Corporation as Toxicology Director for NIEHS, evaluating long-term effects of environmental/food toxins in mice and rats. From there she moved to GTC Biopharmaceuticals and was a member of the team for the first approved transgenic biologic, rhAtryn.

As Director of Toxicology at Millennium, Christina authored and oversaw nonclinical sections of the registration package for Bortezomid (Velcade) for multiple myeloma, and was responsible for the safety program and the standards used for small molecules. As Senior Director of Toxicology at Alnylam Pharmaceuticals, she was responsible for evaluating the first and second generation delivery systems for siRNA, and was part of teams for a number of pharmaceuticals now in the marketplace.

Christina was Senior Director of Toxicology and Bioanalytical at Acceleron (subsidiary of Merck), where she was a member of the development operating committee to review, assess and define strategy of the lead compound Rebloyzl. She also authored IND, CTA, IB, DSUR orphan drug, and pediatric plans, and worked with agencies for carcinogenicity waivers and regulatory response documents.

As Vice President at Voyager Therapeutics (2017-2021), Christina was a member of the Development Leadership Team for five years, where she gained extensive neuroscience experience for advancement of gene therapy compounds.